# TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

> **NCT00102973** · PHASE3 · COMPLETED · sponsor: **Telik** · enrollment: 244 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** TLK286 in Combination with Carboplatin
- **DRUG:** Doxorubicin HCl Liposome Injection

## Key facts

- **NCT ID:** NCT00102973
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2012-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102973, "TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00102973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*